Sunshine Biopharma Inc.

For the period ended Dec 31, 2024. Filed Apr 1, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 1, 2025

SBFM$2.75+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SUNSHINE BIOPHARMA INC.
Dated: April 1, 2025	By:	/s/ Dr. Steve N. Slilaty
		Dr. Steve N. Slilaty, Chief Executive Officer (principal executive officer)
		/s/ Camille Sebaaly
		Camille Sebaaly, Chief Financial Officer (principal financial and accounting officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Dr. Abderrazzak Merzouki
Signature	Title	Date
/s/ Dr. Steve N. Slilaty	Chief Executive Officer and Director	April 1, 2025
Dr. Steve N. Slilaty	(Principal Executive Officer)
/s/ Camille Sebaaly	Chief Financial Officer	April 1, 2025
Camille Sebaaly	(Principal Financial and Accounting Officer)
/s/ Dr. Abderrazzak Merzouki	Director	April 1, 2025
/s/ David Natan	Director	April 1, 2025
David Natan
/s/ Dr. Andrew Keller	Director	April 1, 2025
Dr. Andrew Keller
/s/ Dr. Rabi Kiderchah	Director	April 1, 2025
Dr. Rabi Kiderchah

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.